Investigational New Drugs

, Volume 30, Issue 3, pp 1158–1163 | Cite as

A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium

  • Helen J. MackayEmail author
  • Heather J. Au
  • Elaine McWhirter
  • Thierry Alcindor
  • Andrea Jarvi
  • Katrina MacAlpine
  • Lisa Wang
  • John J. Wright
  • Amit M. Oza


Purpose The Src family of kinases may play a role in the development and progression of gastric cancer. We evaluated the activity and safety of saracatinib an oral, anilinoquinazolone, non-receptor tyrosine kinase inhibitor targeting Src kinases, in patients with metastatic or locally advanced gastric carcinoma. Methods Eligible patients who had received ≤1 prior line of chemotherapy for metastatic disease received saracatinib 175 mg/day of a 28 day cycle until progression. The primary endpoint was the objective response and/or prolonged stable disease rate (pSD ≥ 16 weeks). Results Ten patients with gastric carcinoma and 11 with adenocarcinoma of the gastroesophageal junction received a median of 2 cycles (range 1–10 cycles) of treatment per patient. 17 patients were evaluable for response. No objective response was seen. One patient experienced prolonged Stable disease (pSD). Three patients had SD and 13 progressive disease. Median overall survival was 7.8 months (95% CI, 3.9–12.2 months) and median time to progression was 1.8 months (95% CI: 1.5–1.9 months). Grade 3 events possibly related to saracatinib included: fatigue (2 patients), hypoxia (2) anemia (3) and lymphopenia (2). Conclusion Saracatinib has insufficient activity as a single agent in patients with advanced gastric adenocarcinoma to warrant further investigation. Further development in gastric cancer would require rational drug combinations or identification of a tumor phenotype sensitive to Src inhibition.


Gastric cancer Phase II Saracatinib (AZD0530) Src kinase inhibitor 



This trial was supported by funding from, and drug was supplied by the Cancer Therapeutics Evaluation Program, US National Cancer Institute

Conflict of interest statement

None of the authors of this manuscript have any conflict of interest to declare.


  1. 1.
    Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137–2150PubMedCrossRefGoogle Scholar
  2. 2.
    Jemal A, Siegal R, Xu J et al (2010) Cancer statistics, 2010 CA. Cancer J Clin 60:277–300CrossRefGoogle Scholar
  3. 3.
    Wagner AD, Grothe W, Haerting J et al (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24:2903–2909PubMedCrossRefGoogle Scholar
  4. 4.
    Bang YE, Van Cutsem E, Feyerislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687–697PubMedCrossRefGoogle Scholar
  5. 5.
    Cunningham D, Starling N, Rao S et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36–46PubMedCrossRefGoogle Scholar
  6. 6.
    Kang YK, Kang WK, Shin DB et al (2009) Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III non-inferiority trial. Ann Oncol 20:666–673PubMedCrossRefGoogle Scholar
  7. 7.
    Thomas SM, Brugge JS (1997) Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 13:513–609PubMedCrossRefGoogle Scholar
  8. 8.
    Summy J, Gallick GE (2003) Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 22:337–358PubMedCrossRefGoogle Scholar
  9. 9.
    Yeatman TJ (2004) A renaissance for SRC. Nat Rev Cancer 4:470–480PubMedCrossRefGoogle Scholar
  10. 10.
    Jawhari AUM, Noda M, Pignatelli M et al (1999) Up-regulated cytoplasmic expression, with reduced membranous distribution, of src substrate p 120(ctn) in gastric carcinoma. J Pathol 189:180–185PubMedCrossRefGoogle Scholar
  11. 11.
    Karatzas G, Karayiannakis AJ, Syrigos KN et al (2000) Expression patterns of the E-cadherin-catenin-cell-cell adhesion complex in gastric cancer. Hepatogastroenterology 47:1465–1469PubMedGoogle Scholar
  12. 12.
    Karayiannakis AJ, Syrigos KN, Alexiou D et al (1999) Expression patterns of the novel catenin p120cas in gastrointestinal cancers. Anticancer Res 19:4401–4405PubMedGoogle Scholar
  13. 13.
    Takekura N, Yasui W, Yoshida K et al (1990) pp 60c-src protein kinase activity in human gastric carcinomas. Int J Cancer 45:847–851PubMedCrossRefGoogle Scholar
  14. 14.
    Masaki T, Shiratori Y, Okada H et al (2000) pp 60c-src activation in gastric carcinoma: a preliminary study. Am J Gastroenterol 95:837–838PubMedCrossRefGoogle Scholar
  15. 15.
    Humar B, Fukuzawa R, Blair V et al (2007) Destabilized adhesion in the gastric proliferative zone and c-Src kinase activation mark the development of early diffuse gastric cancer. Cancer Res 67:2480–2489PubMedCrossRefGoogle Scholar
  16. 16.
    Okamoto W, Okamoto I, Yoshida T et al (2010) Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition. Mol Cancer Ther 9:1188–1197PubMedCrossRefGoogle Scholar
  17. 17.
    Gallagher NJ, Lockton AJ, Macpherson M, et al (2005). A phase I multiple ascending dose study to assess the safety, tolerability and pharmacokinetics of AZD0530, a highly selective, orally available, dual specific Src-Abl kinase inhibitor [abstract 3972]. Proc Amer Assoc Cancer Res 46Google Scholar
  18. 18.
    Baselga J, Cervantes A, Martinelli E, et al (2010) Phase I safety, pharmacokinetics, and inhibition of Src activity study of saracatinib in patients with solid tumors. Clin Cancer Res 16:e pub (Oct 1st)Google Scholar
  19. 19.
    Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1–10PubMedCrossRefGoogle Scholar
  20. 20.
    Therasse P, Arbuck S, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors; European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRefGoogle Scholar
  21. 21.
    Moehler MH, Hartmann JT, Lordick F, et al (2010). An open-label, multicenter phase II trial of sunitinib for patients with chemo refractory metastatic gastric cancer. J Clin Oncol 28(suppl; abstr e14503)Google Scholar
  22. 22.
    Yamada Y, Doi T, Muro K, et al (2009) Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer: main results. ASCO Gastrointestinal Cancer Symposium. Abs 77Google Scholar
  23. 23.
    Lara PN, Longmate J, Evans CP et al (2009) A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs 20:179–184PubMedCrossRefGoogle Scholar
  24. 24.
    Bertotti A, Bracco C, Girolami F et al (2010) Inhibition of Src impairs the growth of Met-addicted gastric tumors. Clin Cancer Res 16:3933–3941PubMedCrossRefGoogle Scholar
  25. 25.
    Yoshida T, Okamoto I, Okamoto W et al (2010) Effects of src inhibitors on cell growth and epidermal growth factor receptor and Met signaling in gefitinib-resistant non-small cell lung cancer cells with aquired Met amplification. Cancer Sci 101:167–172PubMedCrossRefGoogle Scholar
  26. 26.
    Fury M, Baxi S, Shen R et al (2011) Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Anticancer Res 31(1):249–253PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Helen J. Mackay
    • 1
    • 7
    Email author
  • Heather J. Au
    • 2
  • Elaine McWhirter
    • 3
  • Thierry Alcindor
    • 4
  • Andrea Jarvi
    • 5
  • Katrina MacAlpine
    • 5
  • Lisa Wang
    • 1
  • John J. Wright
    • 6
  • Amit M. Oza
    • 5
  1. 1.Department of Medical Oncology, Princess Margaret HospitalUniversity of TorontoOntarioCanada
  2. 2.Cross Cancer InstituteUniversity of AlbertaEdmontonCanada
  3. 3.Juravinski Cancer CentreHamiltonCanada
  4. 4.McGill University Health CentreMontrealCanada
  5. 5.Department of Medical Oncology, Princess Margaret Hospital, Drug Development ProgramUniversity of TorontoOntarioCanada
  6. 6.National Cancer InstituteRockvilleUSA
  7. 7.Princess Margaret HospitalTorontoCanada

Personalised recommendations